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INTRODUCTION 
Increased industrialization exposes many populations to greater 
amounts of environmental contaminants. These exposures probably in­
volve several toxicants simultaneously. The lack of public awareness of 
these contacts with contaminants gives people reason for concern. 
Lead is a very common environmental contaminant. This nonessential 
element is deposited in various quantities in organs of humans (Conrad 
and Barton, 1978). The level of lead that shows minimal toxic effect 
is difficult to assess. It is known, however, that nutritional status 
will affect the response of an organism to lead (Levander, 1979). 
Lindane, an organochlorine pesticide, has been used as a soil, 
foliar and seed treatment on a large variety of crops and has been 
used on livestock, pets and agricultural premises (NCI Carcinogenesis 
Technical Report Series No. 14, 1977). Unfortunately, it has residue 
persistence in soil and foods (Reuber, 1979). This compound has re­
cently had its usage reevaluated because of concern for the safety of 
humans and the environment (IDA, 1983). 
Dietary protein is important in detoxifying many toxicants including 
minerals, pesticides, drugs and natural toxicants (Hathcock, 1975). 
Both quality and quantity of protein, especially the quantity of sulfur-
amino acids methionine and cysteine, influences the effectiveness of 
this detoxification. A major importance of these amino acids is in 
the synthesis of glutathione, which is able to conjugate with electro-
philic compounds and metabolites. This conjugation reaction is a de-
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toxification process because the result of the conjugation is the formation 
of a less toxic and more readily excretable compound. Methionine is of 
particular importance because it is the precursor of cysteine and it 
is also an essential amino acid that can be supplied only through the 
diet. These sulfur-amino acids are most abundant in animal protein and 
considerably less so in plant proteins. There has been a growing trend 
to decrease the amount of meat consumption in the United States. The 
use of meat substitutes as alternative protein sources has caused an 
increase in the use of plant proteins such as soybeans in which 
methionine is the first-limiting amino acid. The amount of methionine 
and cysteine in the diet could be reduced significantly depending on 
how much plant protein is substituted for animal protein. 
These considerations suggest that alteration of glutathione 
levels by environmental contaminants may produce toxicities and toxic 
synergisms which could cause a potentiating effect on cell damage in 
individuals consuming marginal or inadequate amounts of methionine. 
The importance of adequate amounts of sulfur-amino acids in the diet 
and their relation to glutathione levels and xenobiotic detoxification 
need to be examined. 
The purpose'of this research project was to investigate the effects 
dietary methionine levels have on lindane and lead effects; the 
possible toxic synergisms that may occur, the involvement of glutathione 
metabolism in these toxicities and what carcinogenic potential, if 
any, may develop from the interactions examined in these experimental 
models. 
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REVIEW OF LITERATURE 
Dietary Methionine and Glutathione 
Methionine is an essential sulfur-containing amino acid required 
for the maintenance of protein equilibrium in humans. The methionine 
requirement may be somewhat reduced if the sulfur-containing non­
essential amino acid cysteine is supplied by the diet (Mitchell et al., 
1976). Cysteine and its precursor methionine are found more abundantly 
in animal protein than plant protein. During digestion, methionine and 
cysteine are released from protein and absorbed into the portal circula­
tion. 
Methionine's functions include methylation reactions where it can 
be used as a methyl donor, for the synthesis of proteins and as a 
precursor of the sulfur atom of cysteine and the 3 carbon propylamine 
moiety of spermine and spermidine (Mudd and Poole, 1975). There is also 
a complicated interrelationship between the effect of methionine and 
vitamin B-12 on folate metabolism. The importance of this interrelation­
ship is evident in vitamin B-12 deficiencies (Stokstad, 1976). Methionine 
also is a potent amino acid in the production of toxic effects. It has 
been suggested that this toxicity could be due to excessive methyl dona­
tion, competitive inhibition of amino acid transport and/or adenosine 
triphosphate (ATP) depletion (Benevenga, 1974). 
Methionine is also used in glutathione (GSH) synthesis. Cysteine, 
which can be synthesized from methionine, combines in a 2-step process 
with glycine and glutamic acid producing GSH (Figure 1). Both steps 
are ATP dependent (Lehninger, 1975). In the production of GSH, the 
L-Glutamlc acid + L-cysKi„e + ATP 
synthetase, Mg , K 
Y-glutamylcysteine + ADP + (1) 
'' Y-Glutamylcysteine + glycine + ATP f~^heSS^ 
y-Glutamylcysteinylglycine (glutathione) + ADP + P^ (2) 
HSCH^CHCONHCH^COgH 
mCOCH^CHgCHCO^H 
Figure 1. Biosynthesis of glutathione 
concentration of cysteine is rate-limiting. Feedback inhibition of 
•y-glutantyl-cysteine synthetase by GSH normally regulates GSH production 
(Meister and Anderson, 1983; Maines, 1981). 
Glutathione is the tripeptide that can be found in nearly all 
cells. It usually is the most abundant sulfhydryl compound present in 
animal tissues and constitutes up to 90 percent of all the nonprotein 
thiols in mammalian cells (White et al., 1978). It can be found in the 
reduced form (GSH) and the oxidized form, glutathione disulfide (GSSG). 
GSH and GSSG are easily interconvarted (Javitt, 1961). Intracellular 
glutathione is found mainly (99%) in the reduced form (GSH) at'a 
concentration of approximately 0.5-10 mM and the extracellular GSH of 
plasma is at only micromolar concentrations (p<M) (Meister and Anderson, 
1983). Intracellular GSH is the source of plasma GSH and GSSG. GSH 
concentrations vary depending on the tissue sampled. The liver of male 
white mice contained the greatest concentration, followed by the spleen, 
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kidney, pancreas, lungs, heart, adrenals and blood (Shaker and 
Soliman, 1966, cited by Chasseaud, 1979). The liver is an 
important organ for biotransformation and GSH levels are relatively 
high there at about 170 mg/100 g in rat tissue (Chasseaud, 1976). 
Intracellular GSH concentrations are susceptible to nutritional status, 
hormonal balance and growth of the organism (Knox, 1960). 
The cellular turnover of glutathione is associated with its trans­
port out of cells in the form of GSH (Meister and Anderson, 1983). 
The rate of GSH turnover vas determined to be the highest in the kid­
ney, followed by liver, pancreas and skeletal muscle when tested in 
mice (Griffith and Meister, 1979). The metabolism of GSH begins with its 
release from cells. It is then transported by blood plasma to the kidney 
or other tissues with substantial transpeptidase activity. GSH in the 
kidney is degraded into a glutamyl group and cysteinyl-glycine through 
the action of y-glutamyl transpeptidase found in the microvilli 
membranes. The Y-glutamyl moiety is joined to an extracellular ac­
ceptor amino acid forming y-glutamyl amino acid which is transported 
into the cell. There it undergoes a series of reactions known as the 
Y-glutamyl cycle. This cycle completes itself by resynthesizing GSH. 
Thus, GSH serves as a transport of amino acids across cell membranes-
(Meister, 1983; Siegers and Younes, 1983; Meister, 1982; Meister, 1981; 
Griffith and Meister, 1979). 
All of the functions of glutathione in biological systems are 
not yet fully understood, but several of its direct and indirect 
functions include: synthesis of proteins and DNA, enzyme ac­
tivity (catalyzing disulfide exchange reactions and serving as a 
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coenzyme for certain enzymes), metabolism and protection of cells (de­
toxifying peroxides and free radicals) (Meister and Anderson, 1983; 
Siegers and Younes, 1983). GSH, for example, aids in preventing 
oxidative damage to erythrocytes. GSH, synthesized in human erythro­
cytes, can with the aid of glutathione peroxidase (a selenium-containing 
enzyme) help detoxify hydrogen peroxide through reduction of the 
peroxide and its oxidation to GSSG. GSSG can then be rapidly reduced to 
GSH by glutathione reductase. GSH can also help prevent oxidation of 
the SH groups of hemoglobin (White et al., 1978). Another less direct 
role liver GSH serves is as a reservoir of cysteine. The cysteine pool 
used for GSH synthesis is kept separate from the cysteine for protein 
synthesis through the presence of GSH (Ketterer et al., 1983; Tateishi 
et al., 1981). 
One of the more important functions of GSH involves its participa­
tion in the formation of a variety of conjugated organic compounds in 
the liver. These are excreted in the bile and/or urine (Chasseaud, 
1979). Metabolism of foreign compounds with GSH followed by the ultimate 
production of mercapturic acid involves conjugation of electrophilic 
compounds with the endogenous nucleophile, GSH. GSH conjugation does 
not require the initial formation of a high energy intermediate in­
volving ATP (Jocelyn, P. C., 1972). The conjugation is generally cata­
lyzed by glutathione S-transferases but it may occur spontaneously. 
Enzymes catalyzing the activation, GSH conjugation and removal of the 
glycine and glutamate moieties occurs predominantly in the liver. 
The final conversion of the GSH conjugate to a mercapturic acid via 
N-acetyl cysteine conjugate formation occurs mainly in the kidney 
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(Moldèus et al., 19T8). 
The metabolism of many environmental contaminants often involves 
two phases. Hydroxylation, reduction and hydrolysis of many compounds 
are some of the common types of reactions occurring in Phase I. The 
most common Phase I system sometimes is referred to as the microsomal 
monooxygenase system, mixed-function oxidase system (MFO) or cyto­
chrome P-450-containing monooxygenases. This microsomal enzyme system 
consists of a membrane-bound multicomponent system localized at high 
concentrations in the endoplasmic reticulum of liver and less so in 
the kidney, lung, intestine, brain and skin. Its constituents are 
NADPH-cytochrome C reductase, cytochrome P-450 and phospholipid. 
Phase II reactions, often the final detoxification step, takes the 
product of Phase I and conjugates it by combining it with another 
compound such as GSH. Some compounds can be conjugated directly 
without any Phase I reaction. The ultimate result of a conjugation with 
GSH is the formation of mercapturic acid which is a nontoxic compound 
that is more excretable (Neal, 1980; Coon, 1978; Williams, 1978). 
Xenobiotic metabolism depends on the following factors (Neal, 1980); 
1. Rate of absorption of the compound; 
2. The ease at which the compound crosses cell membranes; 
3. Whether proteins have the capacity to bind the foreign com­
pounds; 
4. The rate of excretion of the compound; 
5. Species and strain differences in rates of metabolism; 
6. The effect of age, circadian rhythms and nutritional status; 
7. The ability of many compounds to affect hepatic cytochrome 
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P-450-containing monooxygenase activity. 
For example, deficiencies of protein are known to decrease the action 
of MFO enzymes (Campbell, 1978). Glazenburg et al. (1983) studied what 
effects methionine deficient diets had on GSH conjugation of acetaminophen. 
They found that diets with methionine levels as low as 25 percent of the 
control diet (with no cysteine) lowered the liver GSH concentration in 
rats to about 20 percent of the controls. 
Disturbances of GSH and GSSG levels may be induced reversibly or 
irreversibly. Reversible fluctuation of GSH-GSSG status can be brought 
about by GSH-peroxidase, certain metabolites, nonenzymatic oxidation of 
GSH to GSSG, other disulfides, protein and defects associated with GSSG 
reductase. Irreversible GSH and GSSG disturbances can be produced by 
failure of GSH synthesis or reactions where GSH forms conjugates as in 
the case of detoxification reactions (Kosower and Kosower, 1974). 
Many mercapturic acid precursors detoxified through glutathione conjuga­
tion may diminish hepatic GSH stores and that would have important 
toxicological implications (Chasseaud, 1976). 
Glutathione S-Transferases 
The conjugation of GSH with environmental contaminants or Phase I 
biotransformation products is catalyzed by a group of enzymes, the 
glutathione S-transferases (GSH S-transferases), Other GSH conjugations 
are with naturally occurring endogenous compounds such as a-P unsaturated 
compounds (Chasseaud, 1979) or with endogenous substrates such as 
prostaglandins (Chaudhuri et al., 1978; Cagen et al., 1976) and 
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A^-3-ketosteroids (Benson et al., 1977). However, many reactions cata­
lyzed by GSH S-transferases also can proceed nonenzymatically. 
The GSH S-transferase activity appears dependent on 3 factors: 
binding of the substrate to the enzyme, presence of a sufficiently 
electrophilic atom to allow interaction with GSH and increased nucleo-
philicity of the thiol group of GSH (Kaplowitz, 1980). The enzyme 
appears to function by lowering the pK of GSH, causing GSH to ionize at 
physiological pH, thus bringing about a covalent interaction of bound 
cosubstrates through nucleophilic electrophilie-interactions (Keen et al,, 
1975). This reaction neutralizes the electrophilic site on the electro­
philic substrate and renders the product more water-soluble. Metabolism 
continues by cleavage of the glutamate and glycine residues followed 
by acetylation of the resulting free amino acid group of the cysteinyl 
residue to produce a mercapturic acid (Figure 2) (Chasseaud, 1979). 
GSH S-transferases are a family of isoenzymes that appear to be 
genetically related (Ketterer et al., 1983). Six different GSH S-
transferases have been identified (Meister and Anderson, 1983; Habig 
et al., 1974). They are found in the greatest concentration in the 
liver but are known to be present in most cells (Kaplowitz, 1980). Rat 
studies by Kraus and Kloft (1980) showed a surprisingly high level in 
the steroidogenic organs. Levels were less, equal or greater than those 
of the liver depending on the substrate and steroidogenic organ tested. 
Its link here to detoxification is not apparent and is thought to have 
some other special function. However, Polidoro et al. (1980) identified 
GSH S-transferase activity in the human placenta cytosol and suggested 
it to have a detoxifying action against electrophilic compounds. 
10 
R-X + GLUTATHIONE (GSH) 
glutathione 
S-transferase 
\1/ 
R-S-CYS TEINE-GLYCINE 
GLUTAMATE 
Y-glutamyl-
glutamate ^  
transpeptidase 
R-S-CYSTEINE-GLYCINE 
cysteinyl-
glycine ^  
\y 
glycinase 
R-SCH^CHCOOH 
NH„ 
AC-COA N-acetylase 
\/ 
R-SCH^GHCOOH 
NHCOCHg 
Figure 2. Mercapturic acid formation 
Human and rat GSH S-transferases differ in that the human isozymes 
are closely related in amino acid composition, substrate specificity 
and immunologic characteristics (Kamisaka et al., 1975), whereas in the 
rat, GSH S-transferases have overlapping substrate specificities but 
are, for the most part, immunologically distinct (Kaplowitz et al,, 
1976; Habig et al., 1976; Habig et al., 1974; Gillham, 1973). Studies 
with rats showed the transferases differed in activity according to sex, 
age and substrate (Hayakawa, 1977). Other factors that affect GSH 
S-transferase activity in rats are fasting, type of inducers, partial 
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hepatectomy, alcohol pretreatment, experimental diabetes, thyroid dys­
function, cholestasis and liver pre-injury. The effect of each factor 
may vary depending on the substrate involved (Younes et al,, 1980). 
The GSH S-transferases are not only found in the cytosol but can 
also be present in microsomes and mitochondria. Metabolites, some of 
which become substrates for GSH 8-transferase, are produced by the MFO 
system involved in detoxification and localized on the endoplasmic 
reticulum. Most of these substrates are hydrophobic and are expected 
to dissolve in membranes including that of the endoplasmic reticulum 
(Morganstern et al., 1980). Kraus and Gross (1979) found decreased 
concentrations of GSH in liver microsomes and mitochondria when incubated 
with electrophilic compounds. Microsomes appeared less specific in 
substance metabolism than the mitochondria. However, both microsome 
and mitochondrial GSH S-transferase specific activity were lower than in 
the cytosol. DePierre and Morgenstern (1983) indirectly came to the 
conclusion that out of the nine organs tested, the largest capacity for 
conjugation with l-chloro-2,4-dinitrobenzene was liver cytosol* the 
liver endoplasmic reticulum and the testicle cytosol. But 
N-ethyImaleimide-activatable microsomal GSH S-transferase seems only 
to be found in the liver and is absent from the other organs they examined. 
Morgenstern et al. (1979) and Morgenstern et al. (1980) found some in­
ducers of the cytochrome P-450 system increased cytoplasmic GSH S-
transferase activity but did not affect microsomal activity. N-
ethylmaleimide did, however, increase the microsomal activity. Located 
on the cytoplasmic surface of the endoplasmic reticulum, these membrane-
bound microsomal transferases are activated by sulfhydryl reagents and 
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are presumed to be involved in drug metabolism reactions. 
Additional roles have been cited for GSH S-transferase. It ap­
pears it can function as a nonselenium glutathione peroxidase (non-
Se GSH-Px) (Reddy et al., 1981; Burk et al., 1980; Prohaska, 1980). 
Ketterer et al. (1983) purified GSH S-transferase B which showed non-
Se GSH-Px activity. Selenium requiring glutathione peroxidase cata­
lyzes the breakdown of both organic hydroperoxides and hydrogen peroxide 
(HgOg) but non-Se GSH Px breaks down only organic hydroperoxides not 
HgOg (Burk et al., 1980). GSH S-transferases also bind to nonsubstrate 
ligands which has raised questions about their transport and storage 
capabilities. The binding to nonsubstrate ligands include bilirubin. 
It has been proposed that the enzymes have 3 binding locations : a 
glutathione site, an electrophilic substrate site and a nonsubstrate 
binding site. Another possible role for the GSH S-transferases is 
transport. By binding to relatively insoluble compounds at the cell 
membrane and moving them within the cell to sites where biotransforma­
tion can occur, these proteins can have a nonenzymatic role in metabolism 
of foreign compounds. The GSH S-transferases may store compounds by 
binding them within the cytoplasmic compartments, increasing their ap­
parent solubility and preventing diffusion back into plasma (Kaplowitz, 
1980). Bilirubin, a somewhat toxic metabolite of heme, is stored by 
GSH S-transferases until it can be converted into a less toxic compound 
(Wolkoff et al., 1978). GSH S-transferase B was found necessary for the 
release of heme from mitochondria for use by apo-cytochrome P-450 
(Ketterer et al., 1983). A GSH S-transferase, mainly the one called 
ligandin which is identical with GSH S-transferase B, interacts with 
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active intermediates involved in carcinogenesis by covalently binding 
and detoxifying them (Smith et al., 1977). 
GSH S-transferase activity may be regulated by the presence of an 
inhibitor. Boyer et al. (1982) found the activity of the GSH S-
transferase in rat liver microsomes could be increased five fold by 
treating the microsomes with small unilamellar vesicles made with 
phosphatidyl choline (PC). It was suggested that the PC may remove an 
inhibitor of the GSH S-transferases, Lysophosphatidylcholine, bile 
acids and palmitic acid decrease enzymatic activity. It is thought 
that the enzymes' activity is far greater than previously believed 
and its recognized importance as an enzyme in the prevention of toxic 
liver injury has increased. Controversies over many of these enzymes' 
properties still exist with much work remaining in defining their regula­
tion and roles. 
Lindane 
Benzene hexachloride (BHC) or hexachlorocyclohexane is a chlorinated 
hydrocarbon insecticide. Characteristics of this insecticide group include 
presence of carbon, chlorine, hydrogen and sometimes oxygen atoms, the 
presence of cyclic carbon chains including•benzene rings, lack of any 
particular active intramolecular sites, apolarity and lipophilicity and 
chemical inertness. Hence, they are very environmentally stable 
(Figure 3). 
Lindane is the gamma (y)-isomer of BHC. In 1912, it was discovered 
BHC had four isomers; alpha, beta, gamma and theta. Later, BHC was 
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Cl 
H 
Cl Cl 
Figure 3. Molecular structure of lindane^ 
^atsumura, 1975. 
^Chemical structure of lindane (Nakajima, 1983). 
found to have insecticidal properties and the y-isomer was isolated and 
named lindane after Van der Linden. For it to be labelled lindane, the 
BHC preparation must contain 99 percent of the yisomer. Lindane is 
relatively soluble in water and a hundred times more volatile than DDT, 
allowing it to have good fumigant action. It is also more effective 
than the other isomers. The mode of action of BHC as an insecticide is 
to act as an effector of ion permeability. In mammals, it stimulates 
the central nervous system (Matsumura, 1975; McNamara and Krop, 1947). 
Lindane may be said to belong to a similar group of neurotoxicants as 
DDT, though its mode of action is different from that of DDT. Lindane's 
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exact mode of action is not yet known; it attacks the nervous system 
and requires a complete reflex arc to work (Matsumura, 1975). 
In the past, lindane was used in a great variety of ways on crops 
and livestock as an insecticide. However, lindane's usage has been 
limited due to its residue persistance and possible toxic effects. 
Indoor smoke fumigation, dog dips (other than controlling mites), 
aerial application and aquatic application are prohibited. Restricted 
use with certified applicators is allmved for commercial ornamentals, 
pecans, avocados, livestock, Christmas trees, forestry, dog dusts and 
shampoos and structural treatments. Moth sprays, uninhabited buildings 
and storage bin sprays, dog dips to control mites and household products 
other than above require labels to be modified as appropriate to 
reduce applicator risks and require child resistant packaging for 
household products with more than 6.5 percent active ingredient 
(Iowa Department of Agriculture, 1983). 
The entry of insecticides into mammals occurs via the skin, orally 
as residue in food and water, and inhalation. Lindane has relatively 
low skin penetration. Once in the body, the insecticide is usually 
transported and distributed via the bloodstream. After intestinal 
absorption, lindane is carried by lymph until it enters the blood. Most 
lipophilic insecticides are carried in the blood in protein- and 
lipoprotein-associated forms (Morgan et al., 1972). The liver, the 
primary site of detoxification, stores high levels of lindane. 
When the body accumulates more than it can detoxify, residues 
begin to build up. Starvation may cause release of the in­
secticide residue into the bloodstream from the adipose tissue. 
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Srinivasan and Radhakrishnamurty (1983) found rats fed diets with 100 
and 800 ppm lindane for up to 15 days had accumulation of lindane 
residues in this general pattern of distribution, in decreasing order: 
fat, brain, kidney, muscles, lung, heart, spleen, liver and blood. 
Feeding of lindane at 100 and 800 ppm for up to 15 days did not in­
crease tissue residue levels over that of 10 or 5 day fed animals, 
respectively. Also, food restriction (one-third of normal food in­
take) after 15 days of lindane treated diets did not have adverse 
effects on lindane toxicity. Increased brain residue levels were not 
sufficient to cause toxic symptoms and death even though fat and lungs 
did have increases in concentration of lindane. 
Elimination of insecticides may occur through degradation in the 
liver. This organ converts apolar and lipophilic compounds, like the 
chlorinated hydrocarbons, into polar, water-soluble compounds which 
are excreted through the renal system (Matsumura, 1975). 
Movement of BHC into the environment can occur through plant tis­
sues, most importantly agricultural crops. Lindane is translocated up 
through the root system. Soil type also influences the rate of in­
secticide uptake by the plant. The physiochemical characteristics of 
the insecticide determines how long it will remain in the soil. BHC is 
relatively stable and lindane remains in the soil for 3-10 years (Edwards, 
1966). Lindane's volatility allows it to disappear from the soil through 
evaporation into the air (Acree et al., 1963, cited by Matsumura, 1975). 
Stable pesticides such as BHC are only environmentally altered by 
factors such as high alkalinity and high temperatures (Bradbury, 1963). 
In the soil, BHC can degrade into isomers of lindane under anaerobic 
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conditions. Isomerization reactions by microorganisms and selective 
degradation of lindane results in leaving behind the minor isomers of 
lindane, particularly alpha and beta BHC (Matsumura, 1975). 
Toxicity of lindane in mammals stimulates the nervous system, 
raising the blood pressure, causing the heartbeat to fall (bradycardia) 
and produces an irregular encephalogram. Symptoms of BHC poisoning are 
excitation, tremors, ataxia, convulsions, paralysis, and respiratory 
failure which results in death. Lindane has an acute in rats of 
190 mg/kg (Matsumura, 1975). Gaines (1969) found the acute in 
rats to be about 90 mg/kg. A single dangerous dose in man is ap­
proximately 7-15 g, depending on the individual's size, age and state 
of health. The total dietary intake of lindane in the U.S. over a 6-
year period of 1964-1970 was surveyed and found to average 0.05 ng/kg 
body weight/day. The Food and Agricultural Organization-World Health 
Organization (FAO-WHO) acceptable daily intake from food is 12.3 iJ.g 
lindane/kg body weight/day (Duggan and Corneliussen, 1972). The effects 
of lindane at the cellular level may result in enlargement of the liver, 
necrosis, congestion and fatty degeneration of the liver and kidney, 
bladder congestion, hemorrhages of the GI tract, heart and lungs, and 
edema of the brain and spinal cord. Antidotes used for lindane include 
atropine to prevent bradycardia and phénobarbital to counteract rise in 
blood pressure and convulsions (Matsumura, 1975). Accidental lindane 
poisonings have occurred when lindane solutions used for treatment of 
pediculoses and scabies were swallowed or improperly applied externally 
(Davies et al., 1983; Telch and Jarvis, 1982). 
Studies on chronic toxicity of lindane in mammals are not as ex­
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tensive as acute toxicity studies. West (1967) suggested a few cases 
of possible chronic lindane poisonings but Samuels and Milby (1971) 
(cited by Matsumura, 1975) found no clinical indications in their study 
of 79 humans exposed to lindane for several weeks to years. Other 
chronic effects known or suspected to be caused by lindane are 
oncogenicity, teratogenicity and reproductive effects. Studies by 
Nobuyuki et al. (1973) induced hepatocarcinogenesis in mice fed a diet 
containing at least 250 ppm of a-BHC for 24 weeks but no tumors were 
found in the lindane fed mice. Similar results were reported by I to 
et al. (1975). Thorpe and Walker (1973) observed liver enlargement 
and liver lesions in mice fed lindane (400 ppm) for 2 years. Kashyap 
et al. (1979) fed technical grade BHC to mice at 100 ppm for 80 weeks. 
The technical BHC contains 68.7% a-BHC, 6.5% P-BHC and 13.5% y-BHC. 
The treated mice had significant increases in incidences of liver tumors 
and tumors of the lymphoreticular tissue as compared with the control 
mice. The NCI Lindane Rat Study (1977) fed male and female rats pure 
lindane. Increased incidences of carcinomas and neoplasms of endocrine 
organs were found. Thorpe and Walker (1973) fed CFl mice lindane at 400 
ppm for 110 weeks and observed an increased incidence of liver tumors. 
The NCI Mouse Study (1977) fed B6C3F1 mice lindane at 80 or 160 ppm 
for 80 weeks. The treatment was carcinogenic for the liver of the male 
mice and for the spleen of female mice. Other mice and rat studies 
from independent labs indicated similar results. Hanada et al. (1973) 
and Goto et al. (1972) found liver neoplasms in mice fed lindane for 32 
weeks. An 80-week study by Herbst et al. (1975) found no increased 
tumor incidence in mice treated with lindane. The low dosages used in 
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their study offers an explanation for the lack of tumor incidence. 
Rat studies by Ito et al. (1975) found liver hyperplasia occurred from 
lindane treatment. Fitzhugh et al. (1950) fed rats lindane and found 
preneoplastic and neoplastic lesions of the liver, lymphosarcoma of the 
lung, uterine polyps, and polyarteritis of the mesenteric artery. One 
positive effect found from lindane treatment was that on reproduction. 
Wolfe and Esher (1980) found the number of litters produced was higher 
in lindane treated mice. Welch et al. (1969) suggested this effect 
could be due to an estrogenic effect which has been reported for other 
organochlorine insecticides. 
The adverse effects due to acute or chronic exposure to lindane can be 
explained only partially because the exact metabolism of lindane in 
mammals is not fully understood. Several metabolic pathways have been pro­
posed and there is disagreement as to what intermediate compounds are 
formed before final formation of the urinary metabolites. 
In early studies, Grover and Sims (1955) proposed that lindane was 
dehydrochlorinated to 2,3,4,5,6-pentachlorocyclohex-1-ene (y-PCCH) 
which is further metabolized to either 2,4-dichlorophenyl mercapturic 
acid or 2,3,5- and 2,4,5-trichloropheno1 (TCP). Chadwick and Freal 
(1972) found no PCCH or chlorinated benzenes in urinary metabolites. 
Large quantities of 2,3,4,5,6-pentachloro-2-cyclohexen-l-ol (PCCOL) 
were found in the neutral fraction of the urine. In the acid fraction 
of urine, various chlorinated phenols were found. In Chadwick and 
Freal's study, previously unreported metabolites from rats fed lindane 
include 3,4-dichlorophenol, 2,4,6-TCP, 2,3,4,5- and 2,3,4,6-tetrachloro-
phenol (TTCP) and (PCCOL). Chadwick et al. (1975) proposed another path­
way in rats where first the orally administered lindane is dehydrogenated 
to hexachlorocyclohexene (HCCH) and then to PCCOL. They report the 
dehydrogenation step is a cytochrome P-450-dependent mixed function 
oxidase reaction requiring molecular oxygen and reduced nicotinamide 
adenine dinucleotide phosphate (NADPH). Other pesticides have been 
reported to be metabolized via microsomal dehydrogenases but they do 
not require cytochrome P-450 or NADPH. Chadwick et al. (1975) expressed 
disbelief in Grover and Sim's theory because they felt the y-PCCH 
would need to be converted to PCCOL to account for the presence of 
PCCOL identified in the urine. This conversion necessitated a 
hypothesis of an allylic oxidation with a double bond shift. Matsumura 
(1975) suggests perhaps only hydroxylated products can be excreted into 
the urine and that PCCH and tri- and tetrachlorobenzenes were retained 
in the body. This would account for the absence of PCCH and tri- and 
tetrachlorobenzenes in the urine of rats. Aizawa (1982) incorporated 
new research work with Grover and Sim's results and was able to 
demonstrate how both PCCH and PCCOL were intermediates of lindane's 
metabolism. Fitzloff et al. (1982) compared the metabolites of lindane 
produced by human and rat liver microsomes. They identified a second 
form of Y-PCCH not seen before, 3,4,6/5-PCCH, They found 4 major 
primary metabolites 3,6/4,5-HCCH, 3,6/4,5-PCCH, 3,4,6/5-PCCH and 
2,4,6-TCP, and 2 secondary metabolites 2,3,4,6-TTCP and pentachloro-
benzene (PCS) in humans. Rat liver microsomes produce 3,6/4,5-HCCH, 
2,4,6-TCP and 2,3,4,6-TTCP at rates similar to humans but 3,4,6/5-PCCH 
was produced at a much lower rate and 3,6/4,5-PCCH and PCS were 
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not detected. Nakajima (1983) demonstrated the presence of HCCH, PCCOL 
and PCCH metabolites in rat urine. 
Lindane has been shown to induce liver microsomal drug metabolizing 
enzymes in rats (Mikol et al., 1980; Kolmodin-Hedman et al., 1971). 
The induction of these microsomal monooxygenases of the liver and the 
related increased synthesis of cytochrome P-450 occurred when lindane was 
present in the rat diet at concentrations as low as 20 ppm (Pelissier 
and Albrecht, 1976). The effects of lindane on antipyrene metabolism 
led Kolmodin et al. (1969) to conclude that insecticides have the ability 
to induce microsomal drug metabolism in man. Phénobarbital induces 
cytochrome P-450 synthesis whereas me thy 1 cho 1 an thr e ne promotes cytochrome 
P-448 synthesis. Lindane has been demonstrated to be a phenobarbital-
like inducer. Both lindane and phénobarbital pretreatment produced the 
identical benzopyrene (BP) metabolite 4,5-BP-dihydrodiol, which also 
represents a detoxification process (Mikol and Decloitre, 1979). Other 
enzyme systems also appear to be affected by lindane. Tiwari et al. 
(1982a) and Tiwari et al. (1982b) treated rats with lindane orally for 
15 days and found several enzymes affected. L-ascorbic acid has been 
shown to possess protective effects against several toxic compounds. 
Tiwari et al, (1982a) and Tiwari et al. (1982b) wanted to see if L-
ascorbic acid would be effective against lindane. Vitamin C neutralized 
completely or partially the effects lindane had on many of these enzymes 
as well as the animals' growth retardation. 
Glutathione S-transferases are thought to act as the enzyme for 
the conjugation of lindane. Evidence of this was obtained with 
rodents producing mercapturic acids when exposed to BHC isomers and also 
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from GSH conjugation with stereoisomers of PCCH in rat liver cytosol. 
The exact identities of the intermediate product(s) of lindane that 
conjugate with GSH are not fully known (Portig et al., 1979). Earlier 
studies suggest that GSH conjugation of lindane was actually that of 
GSH-y-PCCH via GSH S-transferase (Grover and Sims, 1965; Portig et al., 
1979; Kraus et al., 1981). Nakajima (1983) found di- and tri-
chlorophenylmercapturic acids (DiCPMA and TriCPMA) were formed either 
from conjugation of GSH with y-BHC after dehydrogenation and/or de-
hydrochlorination of lindane occurred. 
Lead 
Lead is a ubiquitous element in the environment. Its early use 
dates as far back as 5000-7000 B.C. (Nriagu, 1978). It was so extensively 
used during the Roman times (water pipes, tiles, storage containers, 
paints, etc.) that widespread lead intoxication has been speculated 
to have been the cause for the decline of the Roman Empire (Gilfillan, 
1965). Modern society has eliminated many unnecessary usages of lead 
but industry still requires lead for batteries, gasoline and other 
products (Gerber et al,, 1980), The health importance of this lead 
contamination is due to contamination of environmental water and air, 
from which it enters the animals and plants used for food, and is 
eventually taken up by humans (Kehoe, 1961). It is fortunate that 
substantial quantities of lead can be stored by humans in the bone in a 
relatively inert form. If lead is mobilized or if lead cannot be stored 
fast enough, lead poisoning occurs (T.G.M.A., 1973). Lead appears to 
23 
have no essential biological function, only toxic effects. 
The threshold of lead toxicity is difficult to define in man be­
cause levels causing toxic symptoms approaches that occurring normally. 
The usual blood levels are in the order of 20 Mg/100 ml. Subclinical 
changes are noted in sensitive persons at 40-60 Mg/100 ml and clinical 
symptoms can arise at levels greater than 60 p.g/100 ml (Gerber et al., 
1980). Clinical symptoms are quite diversified because the biochemical 
changes that occur affect many organs and tissues. Characteristic symp­
toms of lead intoxication involve the following (Gerber et al., 1980): 
(a) hematopoietic system (microcytic anemia from an abnormal and 
impaired production and an increased destruction of red cells); 
(b) nervous system (encephalopathy, mainly in children and peripheral 
neuropathy, mainly in adults); 
(c) kidney (tubular damage in acute intoxication, interstitial-
glomerular fibrosis and tubular atrophy in chronic intoxica­
tion) ; 
(d) gastro-intestinal tract (colic, constipation and diarrhea); 
(e) bone (remodeling of the Haversian system, development of 
radio-dense "lead lines" and formation of giant multinucleate 
cells); 
(f) liver (altered drug metabolism); 
(g) defense mechanisms (bacterial and viral susceptibility in­
creased) ; 
(h) hormones (metabolism of thyroid, pituitary, adrenal and 
sexual hormones are modified). 
Also, lead is known to produce chromosomal abberations but this 
24 
effect appears minor compared with that of other mutagenic agents (Gerber 
et al., 1980). Contradictory results have been published in regard to 
lead and its effects on chromosomes ; thus, its biological significance 
in humans is unknown (Damstra, 1977). Another effect lead has on 
mammals including man is its effects on reproduction. It can prevent 
implantation and delay fetal growth during later stages of pregnancy 
as well as cause neurological damage. Lead is capable of crossing the 
placenta and is considered teratogenic in man depending on the blood 
level of lead in the mother during pregnancy (Gerber et al., 1980). 
All of the adverse effects of lead to mammals are due to its 
(a) biochemical properties and 
(b) metabolism. 
Biochemical properties 
lead", from group .IVA of the periodic table has valence states 
similar to some of the alkaline earths, but its halides, hydroxides and 
phosphates are insoluble. Lead often follows calcium metabolism and can 
act as an antagonist to calcium. It also can be laid down in the 
hydroxyapatite structure of the bone. Lead complexes with organic acids, 
lipids and aromatics (Nriagu, 1978; Venugopal and Luckey, 1978). It also 
complexes with amino acids and is very stable especially with sulfhydryl 
+2 
groups. It can bind to proteins and nucleic acids. Pb disturbs heme 
synthesis by inhibiting the cytoplasmic zinc-dependent, sulfhydryl-rich 
enzyme, aminolevulenic acid dehydratase (ALAD) and the mitochondrial 
sulfhydryl enzyme, ferrochelatase (Hammond, 1977). Lead also binds to 
25 
red cell membranes so that most lead in blood is found in erythrocytes 
(Rosen and Haymovits, 1973). 
Metabolism 
Food, drink and inhalation allow the entrance of lead into the 
body. Once ingested, however, a more complicated situation arises as 
to how much and how the lead is absorbed, distributed, retained or 
excreted. Conrad and Barton (1978) found that in rats, dietary lead 
absorption occurs primarily in the duodenum. There appears to be no 
feedback mechanism because total body content of lead does not affect 
lead absorption. Lead absorption increases with starvation. Aungst 
and Fung (1981a) suggested lead intestinal transport included both a 
carrier-mediated component and passive diffusion and that it may be 
bidirectional, similar to calcium transport. Minerals such as iron, 
zinc and calcium decrease absorption of lead but not by reducing its 
solubility. Competitive inhibition of lead binding to mucosal proteins 
by calcium has also been demonstrated (Barton et al., 1978), sug­
gesting absorption of lead through the gastrointestinal tract is 
regulated and perhaps limited by a requirement of binding to transport 
protein(s) (Aungst and Fung, 1981a). Aungst and Fung (1981a) and Aungst 
et al. (1981) found that the mechanism of transport for lead through 
the rat intestine is largely capacity-limited. Aungst et al, (1981) 
found gavage and drinking water dosing with lead caused blood and organ 
lead concentrations that were not proportional to the dose of lead in 
either adolescent or adult rats. Aungst and Fung (1981b) found that 
intestinal lead absorption in rats was reduced when oral doses of lead 
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were given in the presence of food perhaps due to decreased lead 
solubility or dissolution rate or reduced gastric emptying rate. 
Undernourished rats had similar lead absorption as the controls but 
food deprivation altered the distribution of lead in rats. Age also 
is an important factor in lead absorption. Rader et al. (1981) found 
when immature and adult rats were given drinking water with equal 
concentrations of lead, the younger rats were exposed to greater quantities 
of lead relative to body weight than the older animals. Erythrocytes 
are important in lead transport. Lead is excreted in urine and feces 
and via the bile where the gut is involved. Excretion of lead is limited 
because once lead is stored in bone, it becomes relatively unavailable. 
Lead accumulation in the skeleton accounts for the largest fraction of 
the total body burden of lead, residing there as long as 30 years 
whereas lead in blood and tissues turn over rapidly (Barry, 1978). 
Nutritional factors such as iron, vitamin D, calcium and protein 
also can affect lead absorption. Consumption of deficient or excessive 
amounts of protein can increase the severity of lead poisoning. 
Baltrop and Khoo (1975) found dietary deficiencies of protein were as­
sociated with increased lead concentration in tissue of rats administered 
lead in the diet whereas Quarterman et al. (1978) found increases of 
dietary protein above 20 percent also increased lead retention. Anders 
et al. (1982) studied the effects of different proteins on lead absorp­
tion in rats. They found rats fed a casein + lead diet had blood 
concentrations of lead significantly greater than animals fed soybean meal 
+ lead. Similar effects were found for brain, kidney and .liver tissues. 
Hematocrit and hemoglobin values were also significantly lower in the 
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casein + lead diet compared to the soybean meal + lead diet. Quarterman 
et al. (1980) studied the influence dietary amino acids had on lead 
absorption and found a number of amino acids increased tissue lead 
concentrations, but these decreased, however, as the rats aged. Some rats 
were fed lead and methionine supplements in their semi-synthetic diet 
that already contained casein (22 g/kg). These rats gained more weight 
and had slightly reduced lead content in most tissues, but to a much 
greater extent in the liver, than lead treated rats given no methionine 
supplementation. Other nutritional deficiencies effect lead toxicity. 
Baltrop (1976) found that lead absorption depended upon both quantity 
and type of dietary fat. Both low calcium diets and iron deficiency 
increases lead toxicity. Vitamin E deficiency and lead poisoning together 
produce an anemia in rats that is more severe than that caused by 
either treatment alone (Levander, 1979). 
A less direct effect lead has on heme synthesis is that on cyto­
chrome P-450, a heme containing component of an important microsomal 
enzyme system. Chronic 5-9 week studies involving p.o. (150 or 300 
ppm) or i.p. (20 mg/kg) administration of lead acetate to rats revealed 
that cytochrome P-450 became alternately depressed and elevated 
during the course of treatment (Egan and Cornish, 1973). Similar re­
search was carried out by C. P. Chow and H. H. Cornish (1978). They 
found that one i.p. injection of lead acetate (56 mg/kg) prevented 
the stimulation of zoxazolamine metabolism normally induced by pheno-
barbitol. Lead also delayed phénobarbital induction of hepatic 
microsomal cytochrane P-450 at 12 and 24 hours after treatment but this 
inhibitory effect of lead disappeared by 48 hours. Wagstaff (1979) fed 
28 
rats diets fortified with lead acetate for 10 days and showed stimula­
tion of microsomal enzymes. Besides microsomal enzyme activity, 
glutathione is often measured when analyzing for the metabolism of toxic 
substances including heavy metals such as lead. Dalvi and Robbins 
(1978) found that 24 hours after an i.p. injection of lead acetate 
(100 mg/kg) in mice resulted in depressed GSH levels as well as micro­
somal enzyme activity. Eaton et al. (1980) found when rats were given 
2 i.p. injections of the maximum tolerable dose (MTD) of lead (400 
MM/kg/day) at 36 and 12 hours prior to sacrificing, this decreased 
hepatic cytochrome P-450 content. Only at doses lower than the MTD 
(50 and 100 pM) produced a significant decrease in hepatic GSH content. 
Lead, however, significantly increased renal GSH content at the 2 highest 
levels of lead administration (400 and 200 (JM) . A study of chronic 
lead treatment of dogs (13 weeks) showed no significant changes in 
blood GSH concentration, measured weekly, compared with the control 
animals. The addition of CaEDTA following lead treatment reduced 
clinical signs of lead toxicosis (Mitema et al.. 1980). In vitro 
studies by Reddy et al. (1981) demonstrated that lead inhibited both 
the peroxidase and transferase activities of non-Se GSH-Px isolated from 
calf liver (Reddy et al., 1981). Hsu (1981) studied the effects of 
lead on rat pups born and nourished by dams receiving commercial labora­
tory diet supplemented with 0.5 percent lead acetate. Lead decreased 
hematocrits and increased liver weights and GSH concentrations in 
erythrocytes, liver and kidney. However, glutathione reductase 
and glutathione peroxidase activities were unaffected by lead. Lead 
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enhanced the incorporation of glycine-1- C into kidney GSH and 
29 
3*5 
cystine- S into liver and kidney GSH. From these results, Hsu (1981) 
suggested that lead had a stimulatory effect on the biosynthetic pathways 
of GSH, Lead appeared to disturb protein synthesis by changes in the 
concentration of several free amino acids in the plasma. These changes 
reflected impairment of heme and hemoglobin synthesis and interconversion 
of glycine and serine. 
Extrapolation from animal studies to human beings is extremely 
difficult, partly because combinations of uncontrolled conditions are 
a common phenomena with humans and little can be done to eliminate such 
factors. Usually, the individual is exposed to multiple uncontrolled 
treatments that were not part of the animal study. Such factors can 
involve subtle effects such as those in a person who has multiple 
marginal nutritional deficiencies. There are more obvious effects, 
such as the cyclic hormonal changes found in women. Unknown inhibitory 
or synergistic effects may be present and not realized. For example, 
Maines (1981) found that the inhibitory effects of mercury on GSH 
metabolism could be reversed by selenium. The concomitant exposure of 
rats and mice to the pesticides lindane and zineb showed that lindane pre­
vented zineb's inhibitory and stimulatory effects on liver metabolism of 
aflatoxin (Decloitre and Hamon, 1980). The biggest problem with 
extrapolation of animal study results to humans lies in the variations of 
the methods used in the experiments and the use of different animal 
models. Over and over again statements such as "The results indicate that 
inductive effects are dose dependent, vary with route of administration 
and are selective with regard to different GSH S-transferase activities" 
(Kulkarni et al., 1980) or "enzymatic activity... varies according to 
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species, species-dependent response to inducers or inhibitors, dose 
and duration of exposure to such compounds" (Decloitre and Hamon, 
1980), are being made. Making definite conclusions from animal research 
and applying it directly to humans is difficult but the research does 
have its importance. Especially where toxicology is concerned, ground 
work must be laid and preliminary animal testing must be done to prevent 
avoidable ill-health in humans that could result from lack of basic 
knowledge. 
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MATERIALS AND METHODS 
Experiment I : Animals and Treatments 
Weanling C3H/HEN female mice were randomly assigned to each treat­
ment. The study was conducted with 9 mice per treatment, a total of 
72 mice in all. Animals were housed in rectangular plastic mice cages 
with stainless steel wire tops, 3 mice per cage. The mice were kept 
in a temperature/humidity controlled room with 12 hours of light and 
12 hours of darkness per day. 
3 
The statistical design was a 2 factorial as seen in Table 1. 
Mice were fed either a basal diet that was methionine deficient (MD), 
meeting only 55 percent of the methionine requirement for mice, or 
a methionine sufficient diet (MS), meeting 100 percent of the mouse re­
quirement. The MS diet was the basal diet supplemented with 0.22 per­
cent methionine to meet 100 percent of the methionine requirement for the 
mouse. Both diet groups were given 0 or 250 ppm lead as the acetate in 
drinking water or 0 or 4.6 mg lindane (y-BHC) orally in 0.05 ml corn oil 
once a week or they were given both lead and y-BHC treatments. Mice were 
fed their respective diets for 10 weeks and received their toxicant treat­
ments (lead and y-BHC) the last 9 weeks. Body weights and food consump­
tions (averaged per cage) were measured once a week. 
Diets 
The composition of the basal diet is shown in Table 2. A soy pro­
tein was chosen because it is low in the sulfur amino-acids methionine 
and cysteine. L-methionine was used to supplement the diet to meet 
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Table 1. Experimental design of Experiments I and II 
Methionine sufficient diet Methionine deficient diet 
Control Lead y-BHC Lead Control Lead y-BHC Lead 
Y-BHC y-BHC 
0 250 ppm 4.6 mg Same 0 250 ppm 4.6 mg Same 
doses doses 
100 percent of the mouse requirement for methionine/cysteine (NRC/NAS, 
1978). The Hurley and Bell (1974) vitamin mix was chosen because it 
had been used successfully in previous mouse diets. Additional zinc, 
chromium and selenium were added to Williams and Briggs (modified) 
salt mixture to meet the mouse requirements for minerals (NRC/NAS, 
1978). 
Toxicants 
Lead acetate was added to the drinking water, of the appropriate 
treatment groups, at a concentration of 250 ppm lead. The mice were 
allowed to drink ad libitum. The Y-BHC was purchased from Sigma as 
hexachloro-cyclohexane, a commercial grade powder. The y-BHC was 
mixed in corn oil and given orally at a dose of 4.6 mg once a week for 
a total of 9 weeks. 
Necropsy and Sample Collection 
All mice were decapitated at the end of the experiment. The ab­
dominal cavity was exposed by a longitudinal incision on the midline of 
the abdomen. Examination was made for any abnormalities including 
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Table 2. Composition of basal diet^ for Experiment I 
Ingredient gr/Kg 
Isolated soy protein^ 121.2 
Corn starch 284.4 
Sucrose 284.4 
Beef tallow 190.0 
Safflower oil 10.0 
Cellulose 50.0 
Salt mix^ 50.0 
Vitamin mix*^ 10.0 
Total 1000.0 
^The basal diet contains 55% of NRC mouse requirement for 
methionine and cysteine, 
^Supro 660, Ralston Purina Company, St, Louis, MO. 
"William and Briggs salt mixture (modified), Teklad, Madison, WI, 
with ZnCO] added to provide 14.3 mg Zn/Kg diet, CrCl^*61120 added to 
provide 2.0 mg Cr/Kg diet and Na^SeOg added to provide 1.25 mg Se/Kg 
diet. 
^Mount in 1 Kg diet: vitamin A re tiny 1 palmitate, 1,100 lU; 
vitamin D (cholcalciferol), 1,100 lU; vitamin E (D-L of-tocopherol), 
32 lU; vitamin K (menadione), 18 mg; biotin, 0.2 mg; choline chloride, 
750 mg; folacin, 0.45 mg; niacin, 22.5 mg; Ca-pentothenate, 37.5 mg; 
riboflavin, 7.5 mg; thiamin, 22.5 mg; Bg pyridoxine, 22.5 mg; 3^2 
cobalbamin, 0.023 mg. 
tumor development. Brain, kidney and liver samples were stored in 
formaldehyde for pathological examination. Other liver samples were 
rinsed in 0.05 M potassium phosphate (pH 7.4) prior to freezing in 
liquid nitrogen and then kept frozen for GSH S-transferase analysis. 
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Analytical Methods 
Glutathione S-transferase : The activity of this enzyme was measured 
by a modified method of Booth et al, (1961). For the calculation of 
the enzyme activity, the adaption of AW for l-chloro-2,4-dinitro-
benzene (l-Cl-2,4-DNB) from Habig et al. (1974) was used. The fol­
lowing is the procedure used for the analysis^: 
1. Homogenize liver tissue on ice in 4 volume cold 0.1 M phosphate 
buffer (pH 7.4). 
2. Centrifuge homogenate at 2,000xg for 30 minutes. 
3. Centrifuge supernatant at 95,000xg for one hour. 
4. Reaction mixture for the analysis: 1 mM GSH + 1 mM l-Cl-2,4-
DNB + supernatant + cold 0.1 M KH^PO^ (pH 7.5). 
5. Read cuvettes at 340 im for approximately 5 minutes. 
Experiment II: Animals and Treatments 
The experimental design was the same as that in Experiment I ex­
cept: (a) the diet composition was changed, (b) the diet and lead treat­
ment lasted only 21 days, (c) and a single dose (4.6 mg) of y-BHC was 
given on day 21, 24 hours prior to sacrificing the animals. 
Diets 
The composition of the basal diet was basically the same as that 
used in Experiment I (Table 2) except for the carbohydrate and oil con­
tent as shown in Table 3. 
^All solutions were made fresh daily except buffer. 
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Table 3. Composition of basal diet^ for Experiment II 
Ingredient gr/Kg 
Isolated soy protein^ 101.2 
Corn starch 364.4 
Sucrose 364.4 
Com oil 50.0 
Safflower oil 10.0 
Cellulose 50.0 
Salt mix^ 50.0 
Vitamin mix*^ 10.0 
Total 1000.0 
^The basal diet contains 55% of NRC mouse requirement for 
methionine and cysteine. 
^Supro 660, Ralston Purina Company, St. Louis, MO, 
^Same as in Experiment I. 
*^Sama as in Experiment I. 
Toxicants 
The toxicants were prepared the same as in Experiment I. 
Necropsy and Sample Collection 
All mice were decapitated and blood samples were immediately col­
lected into vials with EDTA and frozen in liquid nitrogen for GSH 
analysis. Midline incisions exposed abdominal cavities for examination 
and sampling of liver and kidney. These tissues were immediately 
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frozen in liquid nitrogen and kept frozen for GSH and GSH S-transferase 
analysis. 
Analytical Methods 
Glutathione S-transferase ; The procedure used was the same as in 
Experiment I. 
Total Protein; Lowry et al. (1951) procedure was used for protein 
analysis so activities of enzymes could be expressed per mg protein. 
Glutathione ; Reduced, oxidized and total glutathione measurements 
of blood, kidney and liver were determined by the fluorometric method. 
A modification was used of Hissin and Hilf's (1976) modified methods 
of Cohn and Lyle's (1966) methods. The following is the procedure used 
for glutathione analysis : 
GSH and GSSG solutions were made in 0,1 M NaH^PO^-0.005 M EDTA 
(PO^-EDTA) buffer (pH 8.0) fresh daily. The o-phthalaldehyde 
(OPTE) solution was a 0.1% (w/v) solution made fresh daily in 
distilled absolute methanol. 
1. Homogenize liver and kidney tissues (100 mg) in 3.75 ml PO^-
EDTA buffer on ice. 
2. Add 1.0 ml 25% HPO3 to homogenate. 
3. Proteins are removed by centrifugation (cold) at 5,000xg 
for 10 minutes and then at 100,000xg for 30 minutes. 
Blood: 
1. Proteins are removed by precipitation with 0.2 ml blood + 
2,0 ml H2O + 0.4 ml 25% HPO3. 
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2. Centrifuge in cold the mixture at 100,000xg for 30 minutes. 
Glutathione (GSH) reaction mixture: 
1. Remove 0.5 ml of kidney or liver supernatant^. 
2. Add 4.5 ml of PO^-EDTA buffer to the supernatant. 
(Steps 1-2 = ASSAY MIXTURE) 
3. Mix 200 Hi of ASSAY MIXTURE + 1.8 ml PO^-EDTA + 100 p-l OPTH. 
4. Incubate 15 minutes at room temperature. 
5. Read fluorescence at 420 nm, determined with activation at 
350 nm. 
Glutathione (GSSG) reaction mixture; 
1. Remove 0.5 ml of kidney or liver supernatant^. 
2. Incubate supernatant at room temperature with 200 pi of 0.04 M 
N-ethylmaleimide for 30 minutes. 
3. Add 4.3 ml of O.IN NaOH to the incubated supernatant. 
(Steps 1-3 = ASSAY MIXTURE) 
4. Mix 200 p,l of ASSAY MIXTURE + 1.8 ml O.IN NaOH + 100 |i-l OPTH. 
5. Incubate at room temperature for 15 minutes. 
6. Read fluorescence at 420 nm, determined with activation 
at 350 nm. 
Standard curve: 
Concentrations for GSH and GSSG ranged from 0.005 M-g to 1.0 ng. 
The buffers used in the standard curve reaction mixture in place of 
the ASSAY MIXTURES should be PO^-EDTA for GSH and O.IN NaOH for GSSG. 
^Use 0.2 ml of blood supernatant and adjust volume with PO4-EDTA. 
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Experiment III: Animals and Treatments 
(Part A) 
Weanling Harlan Sprague Dawley male rats were randomly assigned 
to each treatment. Animals were housed separately in galvanized metal 
rat cages and were kept in a temperature/humidity controlled room with 
a 12-hour light and dark cycle. 
Treatment and diet design consisted of 3 main groups as shown in 
Table 4. Rats were fed either a basal diet that was methionine deficient 
(MD), that met 60 percent of the methionine requirement for the rat, 
or they were fed a methionine sufficient (MS) diet. Both diets were 
also supplemented with lead acetate at 10,000 ppm lead. The MS diet 
consisted of the basal diet supplemented with methionine to meet 100 
percent of the methionine requirement for the rat. The control group 
was fed the MS diet without lead acetate. The animals were fed ad 
libitum. The rats were fed their respective diets a total of 3 
weeks. They were fasted 24 hours on the last experiment day. One 
dose of "Y-BHC was administered orally to the treatment groups 18 hours 
prior to the end of the experiment. Body weights were measured weekly 
and food consumption was measured daily in all groups. 
Diets 
The composition of the basal diet is shown in Table 5. Soy-
protein was chosen as the protein source for its low content in 
methionine and cysteine. The diet was supplemented, where indicated, 
with 0.25 percent L-methionine to meet 100 percent of the rat require­
ment for methionine (NRC/NAS, 1978). 
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Table 4. Experimental design of Experiment III 
MS diet MS diet MD diet 
Control Lead + y-BHC Lead + y-BHC 
0 Lead 10,000 ppm Lead 10,000 ppm 
0 Y-BHC 25% Y-BHC 257= LD^q 
6 rats^ 10 rats 10 rats 
^art B of Experiment III had 7 rats in the control group. 
Toxicants 
Lead acetate was added to the diets at a concentration of 
10,000 ppm lead. y-BHC from Sigma was mixed in corn oil and given 
orally at a dose equal to 25 percent of the for rats (88 mg/kg) 
as reported by Gaines (1969). 
Necropsy and Sample Collection 
All rats were decapitated and blood was immediately collected. 
Hematocrits were measured with fresh blood and the remaining blood 
was stored in vials containing ED TA and stored for determination of 
blood lead levels. A midline incision exposed the abdominal cavity 
for examination. Livers were weighed, then immediately frozen in 
liquid nitrogen and stored at -80°C for GSH and GSH S-transferase 
analysis. 
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Table 5. Composition of basal diet^ in Experiment III 
Ingredient gr/Kg 
Isolated soy protein^ 152.0 
Corn starch 305.0 
Sucrose 310.0 
Cellulose 88.0 
Lard 50.0 
Corn oil 35.0 
Salt mix^ 50.0 
Vitamin mix*^ 10.0 
Total 1000.0 
^The basal diet contains 60% of the NRC rat requirement for 
methionine and cysteine. 
b 
Supro 660, Ralston Purina Company, St. Louis, MO. 
William and Briggs salt mixture (modified), Teklad, Madison, 
WI with NaSeO^ added to provide 0.1 mg Se/Kg diet. 
^AIN vitamin mix 76, U.S. Biochemicals Corp., Cleveland, OH. 
Experiment III: Animals and Treatments 
(Part B) 
Experiment III, Part A, was repeated except the MS (lead and y-BHC) 
treated rats were pair-fed to the MD (lead and y-BHC) treated rats. 
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Analytical Methods 
Glutathione S-transferase : The procedure used was the same as 
in Experiments I and II, 
Total Protein: The Lowry et al. (1951) procedure was used. 
Liver Glutathione; Reduced glutathione (GSH) was determined with 
a modified Ellman's reaction (Jollow et al., 1974), with modifications 
as follows : 
Solutions : 
1. 0.1 M K^PO^ (pH 7.4). 
2. 0.5% NaHCOj*. 
3. Ellman reagent — 40 mg 5,5'-Dithiobis-(2-Nitrobenzoic Acid)/ 
100 ml NaHCO^*. 
4. 4.0% sulfosalicylic*. 
5. GSH standard made in O.IM K^PO^ (pH 7.4)*. 
All solutions with asterisk (*) were made fresh each day. 
Procedure : 
1. Weigh out 0.1-0.15 g liver. 
2. Add 4 times volume of 0.1 M K^PO^ buffer. 
3. Homogenize 10 times with Potter Elvejehm. 
4. Remove 0.5 ml aliquot and add equal volume of 4.0% sulfosali­
cylic acid. 
5. Centrifuge in cold for 30 minutes at lOjOOOxg, 
6. To 0.4 ml aliquots of supernatant add 4,5 ml of Ellman reagent^. 
^Be sure sample supernatant and Ellman reagent are at room temperature 
before reading. Prior to addition of sulfosalicylic acid, tissue sample 
should be on ice. 
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7. Read at 412 nm immediately. 
Standard curve: 
Concentrations for GSH range from 0.0 pg to 80.0 pg. Use 0.1 M 
K^PO^ buffer (pH 7.4) in place of the supernatant. 
Blood Lead; Model 170-70 Hitachi Atomic Absorption (AA) machine 
was used to determine blood lead levels. A stock lead solution containing 
998,000 ppb was purchased from Sigma and used to make a standard 
curve. Actual blood samples were analyzed by mixing 0.05 ml blood to 
1.2 ml 0.1% HNO^. This 1:25 diluted sample was put directly into the 
Hitachi AA machine which dried, ashed and atomized the sample at instru­
ment settings specific for the element lead. 
Experiments I, II and III Statistical Analysis 
The data gathered were analyzed by SAS programming using factorial 
analysis of variance. Program results of the data were compared by 
use of the F-Test (Snedecor and Cochran, 1980) to determine the signifi­
cance levels. However, the data for the mice survival rates (Table 6) 
were statistically analyzed using the Chi-square Test for determining 
significance levels for the proportions dead or alive. 
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RESULTS 
Experiment I 
Lead and lindane (Y-BHC) treatment of the mice fed the methionine 
sufficient (MS) diet had a greater survival rate than those fed the 
methionine deficient (MD) diet (Table 6). The combination of lead 
+ y-BHC had the most negative effect on survival. Only 5 out of 9 
mice were still alive at the end of the experiment in the MD (lead + 
y-BHC) treatment group whereas 8 out of 9 survived in the MS (lead + 
Y-BHC) treatment group. Lead alone had no effect but Y-BHC alone did 
have a significant effect in the MD group. 
Body weight gains of the mice over the 10-week experiment were 
affected most significantly by lead treatment, regardless of the 
methionine status of the diet (Table 7). Lead decreased the overall 
growth rate of the mice. 
The diet had an effect on the total amount of food consumed by 
the mice. The MD fed mice of all 4 treatment groups consumed a greater 
amount of total food than the 4 treatment groups in the MS fed mice 
(Table 8). 
The GSH S-transferase activity, expressed per gram of liver, was 
elevated by the y-BHC treatment. Mice fed the MD and MS diets had in­
creased GSH S-transferase activity levels when they were given y-BHC 
and lead + y-BHC (Table 9). 
Histopathologic evaluation of the mice tissue indicated no signifi­
cant microscopic lesions in either the brain or the kidney. Lesions 
observed in the liver were nonspecific and consisted of the presence 
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Table 6. The effect of dietary methionine, lead and lindane on sur­
vival rate^ (No. survived/starting No.) in mice 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead Y-BEC Lead + None Lead Y-BHC Lead + 
Y-BHC Y-BHC 
9/9 9/9 7/9 5/9 9/9 9/9 9/9 8/9 
^Significant effect of methionine (p < 0.05) and lindane 
(p < 0.0005). 
Table 7. The effect of dietary methionine, lead and lindane on the 
total body weight gain* (grams) in mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead y-BHC Lead + None Lead y-BHC Lead 4 
Y-BHC Y-BHC 
11.17 8.11 9.21 8.90 11.28 9.83 12.94 8.13 
+0.97 +0.95 +1.58 +1.98 +1.12 +0.81 +0.53 +0.74 
^Significant effect of lead (p <0.001). 
Table 8. The effect of dietary methionine, lead and lindane on the 
total food consumed* (grams/cage) by mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead Y'BHC Lead + None Lead Y-BHC Lead + 
y-BHC Y-BHC 
31.20 27.56 30.80 31.87 27.03 26.43 26.27 26.17 
+0.72 +1.07 +0.50 +2.30 +0.66 +0.61 +0.20 +0.19 
^Significant effect of methionine (p < 0.0001) 
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Table 9. The effect of dietary methionine, lead and lindane on the 
liver GSH S-transferase activity^ (lU/g liver tissue) in 
mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead Y-BHC Lead + 
V-BHC 
None Lead Y-BHC Lead + 
Y-BHC 
0.0528 
+0.0014 
0.0551 
+0.0029 
0.0558 
+0.0033 
0.0600 
+0.0047 
0.0548 
+0.0023 
0.0556 
+0.0026 
0.0605 
+0.0027 
0.0607 
+0.0034 
^Significant effect of lindane (p < 0.0203). 
of fine to large vacuoles in hepatocyte cytoplasm, probably an indica­
tion of fatty changes. These histopathological findings appear not to 
be related to toxicant treatments because they were observed in the MS 
control animals as well as in the toxicant treated animals. 
Experiment II 
Weight gain was affected by lead alone regardless of whether the 
diet was MD or MS. The lead decreased body weight gain of both diet 
groups and in the absence or presence of y-BHC treatment (Table 10). 
Liver GSH S-transferase activity was significantly affected by 
the methionine status of the diet. Those mice receiving the MD diet, 
with or without toxicant treatment, had increased transferase activity 
per milligram of liver protein (Table 11). 
Oxidized (GSSG), reduced (GSH) and total glutathione (TGSH) measure­
ments of blood, kidney and liver were not always consistent with one 
another in regard to toxicant and/or diet effect. GSSG was not affected 
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Table 10. The effect of dietary methionine, lead and lindane on the 
total body weight gain^  (grams) of mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead y-BHC Lead + 
y-BHC 
None Lead y-BHC Lead + 
y-BHC 
3.50 
+0.25 
1.61 3.33 
+0.33 +0.49 
2.94 
+0.23 
3.56 
+0.47 
2.56 3.61 
+0.24 +0.47 
3.00 
+0.44 
S^ignificant effect of lead (p < 0.0006) 
• 
Table 11 The effect of dietary methionine, lead and lindane on GSH 
S-transferase activity^  (lU/mg protein) in mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead y-BHC Lead + 
y-BHC 
None Lead y-BHC Lead + 
Y-BHC 
0.0382 
+0.0031 
0.0407 0.0347 
+0.0054 +0.0026 
0.0394 
+0.0033 
0.0299 
+0.0026 
0.0321 0.0281 
+0.0023 +0.0027 
0.0290 
+0.0024 
S^ignificant effect of methionine (p < 0.0004). 
in the kidney, liver or the blood by toxicant or methionine status. 
GSH, however, was affected by lead treatment. Lead increased the GSH 
levels in the kidney, liver and blood. Only in the liver tissue was 
lindane alone found to decrease GSH levels. TGSH was not affected in 
the blood but lead increased the level in the liver. In the kidney, 
TGSH was affected by y-BHC and diet interaction. Lindane and MD diet 
decreased TGSH whereas Y-BHC and MS diet increased TGSH (Tables 12-14). 
There were no deaths of animals in any of the experimental groups. 
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Table 12. The effect of dietary methionine, lead and lindane in 
blood glutathione^  (mg/ml blood) in mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead y-BHC Lead + None Lead y-BHC Lead + 
Y-BHC y-BHC 
GSH 
GSSG 
103.77 165.69 82.74 131.61 82.40 130.26 96.66 135.56 
+21.70 +25.68 +13.74 +27.38 +11.78 +20.35 +20.04 +37.81 
222.97 192,30 209.98 197.65 178.08 204.72 133.75 157.46 
+43.32 +25.71 +46.80 +34.98 +31.39 +34.11 +28.48 +21.93 
„ 326.73 357.99 292.72 329.24 260.47 337.20 230.41 293.03 
+57.75 +43.69 +40.14 +54.13 +35.73 +37.52 +30.69 +47.16 
S^ignificant effect of lead on GSH (p < 0.0042). 
Table 13. The effect of dietary methionine, lead and lindane on 
kidney glutathione^  (t^ g/g liver) in mice (mean + SE) 
GSH 
GSSG 
Methionine deficient diet Methionine sufficient diet 
Toxicant Toxicant 
None Lead y-BHC Lead + None Lead y-BHC Lead + 
y-BHC y-BHC 
TGSH 
276.73 359.59 253. 86 341. 20 243 .51 293.73 272.79 332.93 
+27.78 +36.30 +61. 02 +25. 06 ±35 .63 +26.02 +47.54 +28.10 
293.24 257.84 241. 00 226. 85 211 .32 300.04 343.21 275,36 
+34.40 +47.69 +29. 10 +21. 11 +30 .97 +45.84 +78.91 +48.65 
569.94 617.39 494. 81 568-00 454 .80 593.81 615.97 608,24 
+35.01 +36.16 +69. 04 +40, 15 +46 .72 +42.97 +73.43 +45.76 
S^ignificant effect of lead on GSH (p < 0.0120) and methionine 
X y-BHC interaction on TGSH (p < 0.0417). 
Table 14. The effect of dietary methionine, lead and lindane on liver glutathione^  (|ig/g liver) in 
mice (mean + SE) 
Methionine deficient diet Methionine sufficient diet 
Toxicant ; Toxicant 
None Lead y-BHC Lead + None Lead y-BHC Lead + 
Y-BHC Y-BHC 
GSH 
GSSG 
TGSH 
2957. 41 3424. ,88 2158.76 3121.88 2553.75 2881. 09 2498. 53 2464. 93 
±244. 86 ±232, ,06 ±279.60 ±169.74 ±124.55 ±261. 63 ±314. 28 ±282, ,83 
1447. 69 1902. ,81 1559.24 1763.46 1568.58 1684. 91 1498. 65 1761. 52 
±157. 71 ±185. 37 ±200.80 ±384.33 +134.13 ±123. 99 ±161. 27 +200. 25 
4405. 10 5327. 68 3717.99 4885.35 4122.11 4566. 04 3997. 18 4226. 45 
±343. 14 +305. 46 ±236.00 ±301.10 ±208.73 ±339. 16 ±393. 14 ±250. 84 
S^ignificant effect of lead on GSH (p < 0.0105) and y-BHC on GSH (p < 0.0306) and the effect 
of lead on TGSH (p < 0.002). 
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Experiment III 
By the end of the second week of the experiment for Part A, the MD 
(lead + y-BHC) treated rats began to decrease their food intake and 
did not consume as much as the MS (lead + y-BHC) treated rats. In 
Part B, where the MS (lead + y-BHC) treated rats were pair-fed to the 
MD (lead + y-BHC) treated rats, this was a correct pair-feeding study 
as is indicated by the food consumption data (Table 15). In Part A, both 
MD and lead treatment decreased the animals' food consumption if compared 
to the control rats and MS-lead treated rats. When the MS (lead + -y-BHC) 
treated rats were allowed to eat only the amount the MD (lead + •y-BHC) 
treated rats ate (Part B), methionine deficiency and lead decreased food 
consumption levels for both groups when compared to the control animals. 
No deaths occurred to the rats in any of the treatment groups. 
At the end of the experiments (Parts A and B), the final body 
weights were lower in both diet groups of lead + y-BHC treated animals 
in comparison with the control rats. Both lead and MD diets decreased 
the animals' growth rate. Even when the rats ate the same amount of 
diet as in the pair-feeding groups (Part B), the MD fed group had lower 
body weights than the MS fed group (Table 16). The same trends were 
seen in the average body weight gains per day for diet and lead 
treatment effects (Table 17). 
The effect the methionine status and lead + -y-BHC treatment may 
have on rat liver sizes was analyzed when liver weights were expressed 
as percent of body weight. In both Parts A and B, regardless of 
whether pair-feeding was done or not, MD diets and lead + y-BHC treatment 
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Table 15. The effect of dietary methionine, lead and lindane on the 
average food consumption^  (g/day) by rats (mean + SE) 
None 
Ad libitum feeding 
(Part A) 
Toxicant 
MD diet 
lead+Y-BHC 
MS diet 
lead+Y-BHC 
Methionine sufficient pair-fed 
to methionine deficient 
(Part B) 
Toxicant 
None MD diet 
lead+y-BHC 
MS diet 
lead+y-BHC 
15.32 
+0.34 
9.65 
+0.21 
11.45 
40.37 
14.30 
±0.57 
9.47 
40.37 
9.33 
40.30 
a^rt A — Significant effect of methionine (p < 0.0005) and lead 
(p < 0.0001). Part B — Significant effect of lead (p < 0.0001). 
Table 16. The effect of dietary methionine, lead and lindane on the 
final body weights® (grams) of rats (mean + SE) 
Ad libitum feeding 
(Part A) 
None 
Toxicant 
MD diet 
lead+Y-BHC 
Methionine sufficient pair-fed 
to methionine deficient 
(Part B) 
Toxicant 
MS diet 
lead+y-BHC 
None MD diet 
lead+y-BHC 
MS diet 
lead+y-BHC 
150.67 
+6.46 
74.20 
+2.52 
109.70 
+2.94 
138.29 
+3.73 
71.08 
+1.97 
88.33 
+3.22 
a^rt A — Significant effect of methionine (p < 0.0001) and lead 
(p < 0.0001). Part B — Significant effect of methionine (p < 0.0003) 
and lead (p < 0.0001). 
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Table 17. The effect of dietary methionine, lead and lindane on the 
average body weight gains^  (g/day) of rats (mean + SE) 
Methionine sufficient pair-fed 
Ad libitum feeding to methionine deficient 
(Part A) (Part B) 
Toxicant Toxicant 
None MD diet MS diet None MD diet diet 
lead+y-BHC lead+y-BHC lead+y-BHC lead+y-BHC 
5.73 
+0.33 
1.66 
+0.08 
3.52 
+0.14 
5.07 
+0.14 
1.46 
+0.05 
2.15 
+0.14 
Part A - Significant effect of methionine (p < 0.0001) and 
lead (p < 0.0001). Part B — Significant effect of methionine 
(p < 0.0001) and lead (0 < 0.0002). 
increased the liver weights of rats when compared to the control 
animals (Table 18). However, since Y-BHC was given only once (18 hours 
before the end of the experiment), it is unlikely that y-BHC had any ef­
fect on liver weights or food consumption or body weight data. 
Table 18. The effect of dietary methionine, lead and lindane on 
liver weights^  (% body weights) of rats (mean + SE) 
None 
Ad libitum feeding 
(Part A) 
Toxicant 
MD diet 
lead+y-BHC 
MS diet 
lead+y-BHC 
Methionine sufficient pair-fed 
to methionine deficient 
(Part B) 
Toxicant 
None MD diet 
lead+Y-BHG 
MS diet 
lead+y-BHC 
2.85 
+0.05 
4.98 
+0.25 
3.60 
+0,05 
2.94 
+0.04 
4.74 
+0.22 
3.60 
+0.07 
a^rt A — Significant effect of methionine (p < 0.0001) and lead 
(p < 0.0001). Part B — Significant effect of methionine (p < 0,0002) 
and lead (p < 0.0001). 
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Hematocrits of the rats in both Parts A and B experiments were 
affected by the presence of lead. Lead decreased the hematocrit levels 
in both MS and MD fed rats. No methionine status effect was evident. 
Since y-BHC was administered only once 18 hours before the end of the 
experiment and it is not known to effect hematocrits, the decreased 
hematocrit values are probably not related to y-BHC treatment (Table 19). 
Rats consuming both MD and MS lead supplemented diets (10,000 ppm) 
had very significant increased blood lead levels compared to the con­
trols. Methionine status had no effect on blood lead levels (Table 20). 
GSH S-transferase activity of the liver was expressed per milligram 
of liver protein. Methionine status and/or lead + y-BHC treatment did 
not appear to have any effect on the GSH S-transferase activity (Table 
21).  
Reduced glutathione (GSH) levels of the liver were measured and ex­
pressed three different ways. In the event that the change of the liver 
weights caused by lead and MD diets may have influenced the proportion of 
Table 19. The effect of dietary methionine, lead and lindane on the 
hematocrit values^  (%) of rats (mean + SE) 
Methionine sufficient pair-fed 
Ad libitum feeding to methionine deficient 
(Part A) (Part B) 
Toxicant Toxicant 
None MD diet MS diet None MD diet MS diet 
lead+y-BHC lead+y-BHC lead+y-BHC lead+y-BHC 
39.90 29.25 28.12 38.20 30.34 30.21 
+0.91 +0.58 +0.59 +0.90 +0.65 +1.00 
a^rt A — Significant effect of lead (p <0.0001). Part B — 
Significant effect of lead (p <0.0001). 
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Table 20. The effect of dietary methionine, lead and lindane on 
whole blood lead levels (pg/dl blood) of rats (mean + SE) 
Methionine sufficient pair-fed 
Ad libitum feeding to methionine deficient 
(Part A) (Part B) 
Toxicant Toxicant 
None MD diet MS diet None MD diet MS diet 
lead+y-BHC lead+y-BHC lead+y-BHC lead+y-BHC 
16.88 291.00 332.63 14.87 275.14 297.13 
+2.32 +27.15 +15.30 +1.49 +32.83 +24.87 
a^rt A — Significant effect of lead (p < 0.0001). Part B — 
Significant effect of lead (p < 0.0001). 
Table 21. The effect of dietary methionine, lead and lindane on 
liver GSH S-transferase activity^  (lU/mg protein) of rats 
(mean + SE) 
Ad libitum feeding 
(Part A) 
Toxicant 
None MD diet MS diet 
lead+y-BHC lead+y-BHC 
Methionine sufficient pair-fed 
to methionine deficient 
(Part B) 
Toxicant 
None MD diet MS diet 
lead+y-BHC lead+y-BHC 
0.0264 0.0269 0.0285 0.0211 0.0243 0.0248 
+0.0030 +0.0036 +0.0024 +0.0019 +0.0016 +0.0024 
a^rt A — No significant effect from methionine, lead or y-BHC 
treatment. Part B — No significant effect from methionine, lead or 
y-BHC treatment. 
protein to nonprotein composition of the liver, the GSH measurements were 
expressed as: (a) micrograms per gram of liver tissue, (b) milligrams 
per 100 grams body weight and (c) micrograms per milligrams soluble 
protein. Methionine status and lead + y-BHC treatment both affected 
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GSH levels regardless of how the measurement was expressed. In Part A 
only, the lead + y-BHC treatment increased the GSH level. However, 
when the rats were pair-fed as in Part B, both diet and lead + \-BHC 
treatment affected the GSH levels. Overall, the lead + y-BHC treatment 
increased the GSH levels in both MS and MD fed rats. But the MS 
(lead + -y-BHC) treated rats had higher GSH levels than the MD 
(lead + y-BHC) treated rats (Tables 22-24). 
Table 22. The effect of dietary methionine, lead and lindane on 
liver glutathione (GSH)® (pg/g liver) in rats (mean + SE) 
Methionine sufficient pair-fed 
Ad libitum feeding to methionine deficient 
(Part A) (Part B") 
Toxicant Toxicant 
None MD diet MS diet None MD diet MS diet 
lead+Y-BHC lead+y-BHC lead+y-BHG lead+y-BHC 
775.50 1137.55 1283.68 919.75 974.13 1856.08 
+51.06 ±87.47 ±100.84 ±53.33 ±59.89 ±162.07 
a^rt A — Significant effect of lead + y-BHC (p < 0.0024). 
Part B — Significant effect of methionine (p < 0.0001) and lead + y-BHC 
(p < 0.0002). 
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Table 23. The effect of dietary methionine, lead and lindane on 
liver glutathione (GSH)& (mg/100 g body weight) in rats 
(mean + SE) 
Methionine sufficient pair-fed 
Ad libitum feeding to methionine deficient 
(Part A) (Part B) 
Toxicant Toxicant 
None MD diet MS diet None MD diet MS diet 
lead+Y-BHC lead+y-BHC lead+y-BHC lead+y-BHC 
2.21 5.54 4.63 2.70 4.57 6.73 
+0.16 +0.32 +0.38 +0.17 +0.31 +0.68 
P^art A — Significant effect of lead + y-BHC (p < 0.0003). 
Part B — Significant effect of methionine (p < 0.0085) and lead + 
Y-BHC (P < 0.0002). 
Table 24. The effect of dietary methionine, lead and lindane on 
liver glutathione (GSH)& (ug/mg soluble protein) in rats 
(mean + SE) 
Ad libitum feeding 
(Part A) 
None 
Toxicant 
MD diet 
lead+y-BHC 
Methionine sufficient pair-fed 
to methionine deficient 
(Part B) 
Toxicant 
MS diet 
lead+Y-BHC 
None MD diet 
lead+Y-BHC 
MS diet 
lead+Y-BHC 
7.15 
+0.50 
12.91 
+0.99 
12.16 
+1.44 
8.00  
•K).44 
10.44 
+1.00 
15.43 
+1.54 
a^rt A — Significant effect of lead + Y-BHC (p < 0.0211). 
Part B — Significant effect of methionine (p < 0.0133) and lead + 
Y-BHC (p <0.0011). 
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discussion 
In Experiment I, a 10-week study, the 250 ppm concentration of 
lead as lead acetate in the drinking water was chosen because of an 
earlier study by Fowler et al. (1980) who found that rats treated with 
a nonlethal dose of 250 ppm lead as lead acetate in the drinking water 
for 6-9 months showed physiological and biochemical effects. Fatalities 
occurred in Experiment I, however, only when lead treatment occurred 
simultaneously with lindane treatment or when lindane was the only toxicant 
used with methionine deficient (MD) diets. The dose of 4.6 mg lindane 
administered p.o. to the mice is equal to about twice the dose 
(body weight basis) for the rat. Fatalities were fewer than expected 
probably because of a species difference. But the patterns of the 
deaths that did occur in Experiment I indicated that MD fed mice had a 
lower tolerance level to the lindane and lead + lindane treatment than MS 
fed mice (Table 6). Protein deficiency has been shown to increase pesti­
cide toxicity. Boyd et al. (1970) (cited by Campbell and Hayes, 1976) 
found that the toxicity of lindane was doubled when a 26 percent casein 
diet fed to rats was reduced to 3.5 percent casein. In Experiment II, a 
3-week study, where only one dose (4,6 mg) of lindane was given to the 
mice and Experiment III, also a 3-week study, where only one dose (25% 
of LDgg) of lindane was given to rats, no deaths occurred. Both species 
difference and a shorter treatment period could account for the absence 
of fatalities in Experiment II. Even though rats' were used in Experi­
ment III, fatalities were not expected because of the dose used. 
It is well-known that dietary lead decreases growth rates of rats 
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(Wagstaff, 1979); the results from Experiments I, II and III confirm 
this (Tables 7, 10, 16 and 17). Even with increased food consumption 
by the MD mice in Experiment I (Table 8), the lead + MD fed mice had 
lower body weights. In Experiment III, where lead was increased to 
10,000 ppm, there was also evidence of a MD diet effect as well as a 
lead effect on growth rates of rats. Lead's suppression of growth was 
further enhanced by methionine deficiency. Again, a species difference, 
as well as the fact there was an absence of pair-feeding in Experiments 
I and II, could account for the fact that MD fed mice in Experiments I 
and II did not show a statistically significant methionine effect on 
growth rates. Methionine deficiency increased food consumption of the 
mice in Experiment I. In Experiment III (Part A), however, the MD 
fed rats began to reduce their food intake below that of the MS fed 
rats by the end of week 2 of the experiment. It seems that the in­
creased lead level in the diet of the rats in Experiment III (Part A) 
depressed the appetite stimulation seen in the MD fed mice of Experi­
ment I. Wagstaff (1979) found in rats as the lead concentration in­
creased in the diet food consumption decreased. So, Experiment III 
(Part B) was designed for determining the effects of a true pair-
feeding study. The MS fed rats were only allowed to eat that quantity 
the MD fed rats ate. 
There was considerable variation evident when examining the GSH 
S-transferase results in all 3 experiments. In Experiment I where 
a total of 9 lindane treatments were given to the mice, lindane increased 
• GSH S-transferase activity in both MD and MS fed mice. In Experiment 
II, where lindane was given once, the MD fed mice had a greater GSH 
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S-transferase activity. In Experiment III, where lindane was given 
once, with an increased lead dose and rats were the experimental animal, 
there were no treatment effects. The variation between GSH S-transferase 
activity in Experiments I and II can only be partially explained by a 
difference in the number of lindane doses. The lack of effect that 
methionine deficiency had on GSH S-transferase activity in Experiment I 
could possibly be the result of an adjustment and recovery to the . 
methionine deficiency made over a 10-week treatment period. The lack 
of treatment effects seen in Experiment III (Parts A and B) could be 
due to a species difference. Kulkarni et al. (1980) found that mice 
were more responsive to GSH S-transferase enzyme induction than rats. 
Glutathione levels in Experiment II were affected by toxicant 
treatment and less so by dietary methionine. Reduced glutathione (GSH), 
the form that conjugates with toxicant metabolites, was affected signifi­
cantly, with lead causing an increase in blood, kidney and liver GSH 
levels (Tables 12, 13 and 14). Lead increased total glutathione (TGSH) 
levels only in the liver. Hsu (1981) found that lead had stimulatory 
effects on GSH synthesis. The direct involvement of lead in GSH 
conjugation reactions has not been established. Lindane caused a 
decrease in liver GSH levels, and this was most evident in the MD diet. 
TGSH of the kidney demonstrated a significant lindane and methionine 
effect. Lindane with the MD diet decreased TGSH whereas lindane with 
the MS diet increased TGSH. If enough methionine were present in the 
diet (MS) to make glutathione, perhaps the stimulation of glutathione 
can occur in association with the conjugation of lindane with GSH. 
The overall lack of dietary methionine effect on the toxicant treat­
ments in Experiments I and II could be because the animals in Experi­
ments I and II were not pair-fed. In Experiment III (Part B) where 
the animals were pair-fed, there was a methionine effect. Lead with 
lindane increased GSH levels greater in the MS fed group than the MD 
fed group of rats. The presence of greater quantities of methionine in 
the diet of the MS group appeared to increase production of GSH: a 
greater GSH level was observed. Lead stimulation of GSH synthesis 
perhaps can be enhanced with adequate methionine levels; the conjugation 
of lindane with GSH could also cause increased production of GSH 
when sufficient methionine is present in the animals' diet. 
Hematocrit levels were significantly lowered by the presence of 
high lead levels in the diet of rats (Table 19). Lead is known to 
disturb biosynthesis of heme. Lead inhibits aminolevulinic acid de­
hydratase (ALAD) required for porphobilinogen (PGB) formation (Hsu, 1981). 
In spite of lead causing apparently increased GSH levels, lead's 
role as a detoxifier is not certain for other substances. Lead has been 
shœzn in different experiments to increase and decrease the microsomal 
enzymes of Phase I reactions in drug detoxification (Eaton et al., 
1980; Wagstaff, 1979; Chow and Cornish, 1978; Dalvi and Robbins, 1978; 
Egan and Cornish, 1973). Variability in these experiments in regard 
to the lead doses and route of administration could be the cause of the 
conflicting results. 
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summary 
When the toxicants lead and lindane were given to mice orally in 
conjunction with a methionine deficient (MD) diet, more fatalities oc­
curred than in those mice fed a methionine sufficient (MS) diet. 
Lead supplemented food fed to mice and rats decreased their growth 
rates. High levels of lead (10,000 ppm) in the diet of the rat de­
creased their food intake as well as their hematocrits. Lead feeding 
apparently increased liver glutathione (GSH) levels. And when MS (lead + 
Y-BHC) treated rats were pair-fed to MD (lead + y-BHC) treated rats, the 
MS (lead + y-BHC) treated rats had a higher level of GSH. The methionine 
status of the animals appears to be an important factor in determining 
its liver GSH level. 
When studying parameters such as lethal doses of lindane, body 
weights and methionine status and GSH S-transferase activity, there 
appeared to be a species difference when comparing rat and mice results. 
When treated only once, all the mice survived a dose of lindane that 
was twice the LD^  ^dose for rats. Mice body weights were less affected 
by methionine deficiency than the rats. GSH S-transferase activity 
in mice demonstrated treatment effects. In rats, however, no treatment 
effects were evident for GSH S-transferase activity. 
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